Circadian variation inO6-alkylguanine-DNA alkyltransferase activity in circulating blood mononuclear cells of healthy human subjects
Open Access
- 8 December 2000
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 91 (1) , 60-66
- https://doi.org/10.1002/1097-0215(20010101)91:1<60::aid-ijc1010>3.0.co;2-n
Abstract
Cytotoxic agents such as chloroethylnitrosoureas (CENUs) mostly alkylate DNA on the O6-guanine position. This highly mutagenic lesion can be repaired by O6-alkylguanine-DNA alkyltransferase (AGT), which removes the alkyl group by accepting it to the cysteine residue of its active site. AGT activity displayed a circadian rhythm in mouse liver, coincident with that of CENU tolerability. We investigated whether AGT activity displayed a circadian rhythm in human circulating mononuclear cells (MNCs). The study was performed in 12 healthy volunteers aged 19 to 31 years. Circadian synchronization was verified with rest/activity cycle as assessed with wrist actigraphy and plasma cortisol and melatonin rhythms. Subjects were hospitalized for 24 hr and blood samples were obtained at 08:00, 12:00, 16:00, 20:00, 22:00, 00:00, 02:00, 04:00 and 08:00 overnight. MNCs were isolated on Ficoll immediately after blood sampling and frozen at −196°C until AGT activity determination by HPLC. Mean AGT activity (± SEM) varied from 821 ± 67 fmol/mg of total proteins at noon (trough), up to 1055 ± 80 fmol/mg at midnight (peak), i.e., by ∼30%. A circadian rhythm was statistically validated with both analysis of variance (p < 0.009) and cosinor (p < 0.02) for AGT activity in MNCs (acrophase ± SD at 00:30 ± 210 min) as well as for MNC circulating count and for plasma cortisol and melatonin concentrations. Despite individual variations in the extent of AGT activity rhythm (more or less pronounced according to subject), AGT activity displayed a circadian rhythm in human MNCs of our healthy study group subjects. The results warrant to further investigate AGT rhythmicity both in circulating MNCs and in target tissues of cancer patients, as a prerequisite for clinical testing of chronotherapy with alkylating agents. Int. J. Cancer 91:60–66, 2001.Keywords
This publication has 34 references indexed in Scilit:
- Relationship of atypical melatonin rhythm with two circadian clock outputs in B6D2F1 miceAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2000
- Modulation of nonprotein sulphydryl compounds rhythm with buthionine sulphoximine: relationship with oxaliplatin toxicity in miceArchives of Toxicology, 1998
- Pharmacologic Modulation of Reduced Glutathione Circadian Rhythms with Buthionine Sulfoximine: Relationship with Cisplatin Toxicity in MiceToxicology and Applied Pharmacology, 1997
- Circadian rhythm in toxic effects of cystemustine in mice: Relevance for chronomodulated deliveryInternational Journal of Cancer, 1996
- Circadian variation in O6-methylguanine-DNA methyltransferase activity in mouse liverAnti-Cancer Drugs, 1996
- Glutathione and related enzymes in multidrug resistanceEuropean Journal Of Cancer, 1996
- Effect of alkyl-N-purine DNA glycosylase overexpression on cellular resistance to bifunctional alkylating agentsBiochemical Pharmacology, 1995
- A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancerCancer, 1992
- Cytostatic action of two nitrosoureas derived from cysteamineBritish Journal of Pharmacology, 1986
- New cysteamine (2-chloroethyl)nitrosoureas. Synthesis and preliminary antitumor resultsJournal of Medicinal Chemistry, 1985